Anzeige
Erschienen in:
03.12.2019 | Humane Papillomaviren | Prävention
Update HPV-Impfung
Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz | Ausgabe 4/2019
Einloggen, um Zugang zu erhaltenBitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Literatur
1.
Zurück zum Zitat Garland SM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943CrossRef
Garland SM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943CrossRef
2.
Zurück zum Zitat Ghelardi A et al (2018) SPERANZA project: HPV vaccination after treatment for CIN2+. Gynecol Oncol
Ghelardi A et al (2018) SPERANZA project: HPV vaccination after treatment for CIN2+. Gynecol Oncol
3.
Zurück zum Zitat Giuliano AR et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364(5):401–411. https://doi.org/10.1056/NEJMoa0909537 CrossRefPubMedPubMedCentral
Giuliano AR et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364(5):401–411. https://doi.org/10.1056/NEJMoa0909537 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kjaer SK et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868–878. https://doi.org/10.1158/1940-6207.CAPR-09-0031 CrossRef
Kjaer SK et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868–878. https://doi.org/10.1158/1940-6207.CAPR-09-0031 CrossRef
5.
Zurück zum Zitat Tabrizi SN et al (2014) Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 14(10):958–966. https://doi.org/10.1016/S1473-3099(14)70841-2 CrossRefPubMed
Tabrizi SN et al (2014) Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 14(10):958–966. https://doi.org/10.1016/S1473-3099(14)70841-2 CrossRefPubMed
6.
Zurück zum Zitat Hartwig S et al (2017) Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9‑valent HPV vaccine types in women and men in Europe. Infect Agent Cancer 12:19. https://doi.org/10.1186/s13027-017-0129-6 CrossRefPubMedPubMedCentral
Hartwig S et al (2017) Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9‑valent HPV vaccine types in women and men in Europe. Infect Agent Cancer 12:19. https://doi.org/10.1186/s13027-017-0129-6 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hartwig S et al (2015) Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res 1:90–100. https://doi.org/10.1016/j.pvr.2015.06.003 CrossRefPubMedCentral
Hartwig S et al (2015) Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res 1:90–100. https://doi.org/10.1016/j.pvr.2015.06.003 CrossRefPubMedCentral
8.
Zurück zum Zitat Garland SM et al (2015) Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 33(48):6855–6864. https://doi.org/10.1016/j.vaccine.2015.08.059 CrossRefPubMed
Garland SM et al (2015) Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 33(48):6855–6864. https://doi.org/10.1016/j.vaccine.2015.08.059 CrossRefPubMed
9.
Zurück zum Zitat Dietrich L et al (2019) HPV-Impfung: Update 2019 für die Impfberatung. Schweiz Med Forum 19(1314):220–226
Dietrich L et al (2019) HPV-Impfung: Update 2019 für die Impfberatung. Schweiz Med Forum 19(1314):220–226
Metadaten
- Titel
- Update HPV-Impfung
- verfasst von
-
Dr. med. Brigitte Frey Tirri
- Publikationsdatum
- 03.12.2019
- Verlag
- Springer Vienna
- Schlagwörter
- Humane Papillomaviren
Gynäkologie und Geburtshilfe - Erschienen in
-
Journal für Gynäkologische Endokrinologie/Schweiz
/ Ausgabe 4/2019
Print ISSN: 1995-6924
Elektronische ISSN: 2520-8500 - DOI
- https://doi.org/10.1007/s41975-019-00123-1
Bildnachweise
Impfen/© Julian Stratenschulte / dpa / picture alliance